Frank Ruffo, Chief Financial Officer at Aclaris Therapeutics, Inc. (ACRS), sold 114,578 shares at $25.79 ($3.0M) on 2021-04-26, disclosed to the SEC on 2021-04-26.
Open-market sale of $3.0M ACRS by Chief Financial Officer. Not flagged as scheduled, tax-driven, or recurring — but no specific bearish signal from our filters. Reasons for insider sales vary widely.
Something here stands out, but not much.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $26.84 | 30,000 | $805K | 26.7% |
| 2 | $26.64 | 29,200 | $778K | 25.8% |
| 3 | $27.33 | 800 | $22K | 0.7% |
| 4 | $25.79 | 27,239 | $702K | 23.3% |
| 5 | $25.79 | 27,239 | $702K | 23.3% |
| 6 | $26.44 | 100 |
| $3K |
| 0.1% |
| Total | $26.29 avg | 114,578 | $3.0M | 100% |
| Filing → |
| ACRS | SELL | 2021-06-02 | $596K | — | Filing → |
| ACRS | BUY | 2018-05-07 | $23K | — | Filing → |
| ACRS | BUY | 2018-04-09 | $21K | — | Filing → |